MX342907B - El uso de un anticuerpo anti-cd52 monoclonal para el tratamiento de lupus. - Google Patents

El uso de un anticuerpo anti-cd52 monoclonal para el tratamiento de lupus.

Info

Publication number
MX342907B
MX342907B MX2011012048A MX2011012048A MX342907B MX 342907 B MX342907 B MX 342907B MX 2011012048 A MX2011012048 A MX 2011012048A MX 2011012048 A MX2011012048 A MX 2011012048A MX 342907 B MX342907 B MX 342907B
Authority
MX
Mexico
Prior art keywords
methods
compositions
treating lupus
patient
lupus
Prior art date
Application number
MX2011012048A
Other languages
English (en)
Other versions
MX2011012048A (es
Inventor
Johanne M Kaplan
Bruce L Roberts
William M Siders
Original Assignee
Genzyme Corp *
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp * filed Critical Genzyme Corp *
Publication of MX2011012048A publication Critical patent/MX2011012048A/es
Publication of MX342907B publication Critical patent/MX342907B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2893—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2026—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Abstract

La presente invención se refiere a métodos para tratar el lupus en un paciente con un anticuerpo anti-CD52; asimismo incluye métodos para incrementar la infiltración de células T reguladoras a lugares afectados del cuerpo del paciente, métodos para reducir los niveles de proteína y/o albúmina en orina y métodos para reducir los linfocitos para aliviar los síntomas del lupus.
MX2011012048A 2009-05-13 2010-05-13 El uso de un anticuerpo anti-cd52 monoclonal para el tratamiento de lupus. MX342907B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17792409P 2009-05-13 2009-05-13
PCT/US2010/034741 WO2010132683A1 (en) 2009-05-13 2010-05-13 Methods and compositions for treating lupus

Publications (2)

Publication Number Publication Date
MX2011012048A MX2011012048A (es) 2011-12-12
MX342907B true MX342907B (es) 2016-10-17

Family

ID=43085330

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011012048A MX342907B (es) 2009-05-13 2010-05-13 El uso de un anticuerpo anti-cd52 monoclonal para el tratamiento de lupus.

Country Status (12)

Country Link
US (2) US9617343B2 (es)
EP (2) EP2429583A4 (es)
JP (3) JP5834004B2 (es)
KR (1) KR101800467B1 (es)
CN (2) CN102438654A (es)
AU (2) AU2010248935B2 (es)
BR (1) BRPI1013927A2 (es)
CA (1) CA2761885A1 (es)
IL (1) IL216146A0 (es)
MX (1) MX342907B (es)
RU (1) RU2607022C2 (es)
WO (1) WO2010132683A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2429582A4 (en) 2009-05-13 2013-01-23 Genzyme Corp IMMUNOGLOBULINS ANTI-CD52 HUMAN
WO2013107413A1 (zh) * 2012-01-19 2013-07-25 中国科学院上海巴斯德研究所 磷酸化途径相关因子在调控调节性t细胞功能中的应用
EP3789497B1 (en) * 2013-02-08 2024-01-03 Allegheny-Singer Research Institute Cell-bound complement activation products as diagnostic biomarkers for pre-lupus
AR095199A1 (es) 2013-03-15 2015-09-30 Genzyme Corp Anticuerpos anti-cd52
MX2015013364A (es) * 2013-03-20 2015-12-15 Hoffmann La Roche Deteccion especifica de anticuerpos de rata en suero de raton.
PT3105317T (pt) 2014-02-14 2019-02-27 Cellectis Células para imunoterapia manipuladas para atuar sobre antigénios presentes tanto em células imunitárias como em células patológicas
AU2016225012B2 (en) * 2015-02-27 2020-09-03 Kevin Chen Chimeric antigen receptors (CARS) targeting hematologic malignancies, compositions and methods of use thereof
US11173179B2 (en) 2015-06-25 2021-11-16 Icell Gene Therapeutics Llc Chimeric antigen receptor (CAR) targeting multiple antigens, compositions and methods of use thereof
SG10201913682QA (en) 2015-06-25 2020-03-30 Icell Gene Therapeutics Llc CHIMERIC ANTIGEN RECEPTORS (CARs), COMPOSITIONS AND METHODS OF USE THEREOF
EP3474867A4 (en) 2016-06-24 2020-05-20 iCell Gene Therapeutics LLC CHIMERIC ANTIGEN (CAR) RECEPTORS, COMPOSITIONS AND RELATED METHODS

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9022547D0 (en) 1990-10-17 1990-11-28 Wellcome Found Purified immunoglobulin
GB9022543D0 (en) 1990-10-17 1990-11-28 Wellcome Found Antibody production
GB9125768D0 (en) 1991-12-04 1992-02-05 Hale Geoffrey Therapeutic method
US7119248B1 (en) 1994-04-12 2006-10-10 Miltenyi Biotec Gmbh Antibodies against epitopes with homology to self antigens, methods of preparation and applications thereof
US7060802B1 (en) * 2000-09-18 2006-06-13 The Trustees Of Columbia University In The City Of New York Tumor-associated marker
US7465790B2 (en) 2000-10-09 2008-12-16 Isis Innovation, Inc. Therapeutic antibodies
WO2004042032A2 (en) * 2002-11-01 2004-05-21 The Ohio State University Research Foundation Cytogenetic abnormalities that are predictive of response to therapy for chronic lymphocytic leukemia
US7534427B2 (en) 2002-12-31 2009-05-19 Immunomedics, Inc. Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
EP1618891A1 (en) 2003-03-31 2006-01-25 Kirin Beer Kabushiki Kaisha Method of inducing differentiation and proliferating regulatory t cell by anti-cd52 antibody and medicinal composition therefor
EP1694706B1 (en) 2003-11-01 2012-04-04 Merck Patent GmbH Modified anti-cd52 antibody
EP1755673B1 (en) 2004-04-12 2014-07-23 MedImmune, LLC Anti-il-9 antibody formulations and uses thereof
CN101443040A (zh) * 2006-03-16 2009-05-27 基因技术股份有限公司 用cd4抗体治疗狼疮的方法
AU2007348315A1 (en) 2006-04-07 2008-09-12 Chimeros, Inc. Compositions and methods for treating B- cell malignancies
ES2547333T3 (es) * 2006-04-12 2015-10-05 Genzyme Corporation Métodos para tratar enfermedades autoinmunes
GB0608054D0 (en) 2006-04-24 2006-05-31 Isis Innovation Production and use of regulatory t cells
EP2029729A2 (en) * 2006-05-31 2009-03-04 Genzyme Corporation Methods of using anti-thymocyte globulin and related agents
ES2612383T3 (es) 2006-07-19 2017-05-16 The Trustees Of The University Of Pennsylvania WSX-1/IL-27 como una diana para respuestas antiinflamatorias
WO2008140484A2 (en) 2006-11-09 2008-11-20 Xdx, Inc. Methods for diagnosing and monitoring the status of systemic lupus erythematosus
EP2429582A4 (en) * 2009-05-13 2013-01-23 Genzyme Corp IMMUNOGLOBULINS ANTI-CD52 HUMAN
AR095199A1 (es) 2013-03-15 2015-09-30 Genzyme Corp Anticuerpos anti-cd52

Also Published As

Publication number Publication date
CA2761885A1 (en) 2010-11-18
CN110179989A (zh) 2019-08-30
AU2017201771A1 (en) 2017-04-06
US20170369583A1 (en) 2017-12-28
EP2429583A4 (en) 2013-10-16
KR101800467B1 (ko) 2017-11-22
RU2607022C2 (ru) 2017-01-10
EP3345620A1 (en) 2018-07-11
AU2010248935A1 (en) 2011-11-17
JP2015052021A (ja) 2015-03-19
JP2017008106A (ja) 2017-01-12
US20120070408A1 (en) 2012-03-22
US9617343B2 (en) 2017-04-11
RU2011150495A (ru) 2013-06-20
MX2011012048A (es) 2011-12-12
KR20140014392A (ko) 2014-02-06
JP2012526846A (ja) 2012-11-01
WO2010132683A1 (en) 2010-11-18
JP5834004B2 (ja) 2015-12-16
BRPI1013927A2 (pt) 2016-04-05
AU2010248935B2 (en) 2016-12-15
CN102438654A (zh) 2012-05-02
IL216146A0 (en) 2012-01-31
CN110179989B (zh) 2022-06-24
EP2429583A1 (en) 2012-03-21

Similar Documents

Publication Publication Date Title
MX342907B (es) El uso de un anticuerpo anti-cd52 monoclonal para el tratamiento de lupus.
MX343747B (es) Agentes de union diana contra b7-h1.
SG158112A1 (en) Hepatocyte growth factor (hgf) binding proteins
EA201500393A1 (ru) Ингибиторы тирозинкиназы брутона
MY160041A (en) Compositions and methods for treating parasitic infections
JO2828B1 (en) Anti-Hepsidine antibodies and their uses
WO2009099677A3 (en) Therapeutic peptidomimetic macrocycles
MX348735B (es) Celulas madre mesenquimales que expresan los receptores tnf-alfa.
MA33208B1 (fr) Anticorps anti-fgfr3 et procédés d'utilisation de ceux-ci
EA201071421A1 (ru) Анти-flt3 антитела
WO2012087742A3 (en) Methods and compositions suitable for managing blood glucose in animals
SG169327A1 (en) Compositions and methods of use for antibodies of dickkopf-1 and/or -4
SG166093A1 (en) Inhibitors of brutonæs tyrosine kinase
MA33256B1 (fr) Anticorps et immunoconjugués anti-fcrh5 et procédés d'utilisation
WO2008034076A3 (en) Cyclophosphamide in combination with immune therapeutics
MA34722B1 (fr) Méthodes et compositions pour l'immunothérapie de maladies neurales
UA101814C2 (ru) Фактор, задействованный в латентной инфекции герпесвирусом, и его применение
NZ605873A (en) Methods and compositions for cns delivery of arylsulfatase a
MY166537A (en) Human monoclonal antibody with specificity for dengue virus serotype 1 e protein and uses thereof
WO2008112003A3 (en) Targeted binding agents directed to pdgfr-alpha and uses thereof
WO2009023333A3 (en) Inhibition of the sh2-domain containing protein tyr-phosphatase, shp-1, to enhance vaccines
MA35165B1 (fr) Induction de tolérance immune par utilisation de méthotrexate
WO2010124101A3 (en) Genetic markers associated with endometriosis and use thereof
MA34541B1 (fr) Compositions d'anticorps et procédés d'utilisation
AU2016204146A1 (en) Methods of Increasing Neuronal Differentiation Using Antibodies to Lysophoshatidic Acid

Legal Events

Date Code Title Description
FG Grant or registration